Abstract P3-07-07: Incidence and survival among breast cancer patients in the United States by race and stage diagnosis: an analysis of national registry data 2000–2009

Abstract

Abstract BACKGROUND: This study evaluated incidence and survival among breast cancer (BC) patients in the United States during 2000–2009, by race and stage at diagnosis. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database was used for this analysis. SEER is an epidemiologic surveillance system consisting of population-based tumor registries designed to track cancer incidence and survival in the US. The registries routinely collect information on incident cancer cases in areas that represent approximately 25% of the US population. We evaluated age-adjusted (to the 2000 US standard population) incidence (number of cases per 100,000 population), and 1- and 5-year survival among newly diagnosed female breast cancer patients during 2000–2009, by cancer stage (localized, regional, distant and unknown/unstaged) and race (White, Black, Other [American Indians/Alaska Natives or Asians/Pacific Islanders]). RESULTS: A total of 543,539 cases of female BC were reported to SEER during 2000–2009, with 452,047 cases among Whites (W), 54,310 cases among Blacks (B), and 37,182 among other races (O). The overall incidence was highest for Whites (130.2 per 100,000 population), followed by Blacks (120.1) and other races (59.6–93.2). Similarly, incidence of localized BC was highest among Whites (81.1), followed by Blacks (63.0) and other races (35.4–58.7). Blacks had the highest incidence of regional (43.6 vs. 18.8–40.1), distant (9.7 vs. 3.7–6.0), and unknown stage of BC (3.8 vs. 1.6–3.0) compared to Whites and other races. Incidence of localized BC decreased slightly for Whites (average annual change −0.4%) during 2000–2009; however it increased for all other groups (1.4–1.8%). Incidence of distant BC increased for all races (W: 1.0%, B: 2.3%, O: 3.1–3.8%). Blacks had the lowest one-year and five-year survival for localized, regional and distant BC. One-year and five-year survival rates were relatively stable during 2000–2009 for regional and localized BC (annual average change: −0.6% to 0.7%), for all races. For distant BC, Blacks had least improvement during 2000–2009 in one-year survival (annual average change 0.03%, vs. 0.6% for Whites and 3.6% for other races), and decreasing five-year survival (annual average change −5.4% vs. 2.2% for Whites and 1.7% for other races). CONCLUSIONS: Based on US population-based registry data, Blacks had higher incidence of more advanced breast cancer and lower long-term survival for all stages of BC. There is considerable room to improve survival rates for patients with regional and distant BC, especially among Blacks. Further studies evaluating the survival experience of later-stage BC patients based on other key factors, such as age, socioeconomic status, treatment patterns, and tumor characteristics (e.g. ER/HER2 status) are warranted. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-07-07.